Marketing Analytics Manager

Twist Bioscience (NASDAQ:TWST) stock: insider Adam Laponis sells 8,057 shares. October 5, 2026 Key points. * CFO Adam Laponis sold 8,057 Twist Bioscience shares for approximately $1.52 million at an average price of $188.88, reducing his position by 7.42%. The sale was made to cover tax withholding obligations tied to vested equity awards. * Twist shares recently traded near a 52-week high at $205, with a market capitalization of about $12.86 billion. Despite strong momentum and 23.2% year-over-year revenue growth, the company remains unprofitable and its latest quarterly EPS missed analyst expectations. * Analyst sentiment remains generally positive, with a consensus rating of "Moderate Buy," although the average price target of $115.27 is well below the recent share price, highlighting valuation and volatility risks. * Interested in Twist Bioscience? Here are five stocks we like better. Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 8,057 shares of the firm's stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,521,806.16. Following the sale, the chief financial officer owned 100,576 shares of the company's stock, valued at approximately $18,996,794.88. This represents a 7.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Adam Laponis also recently made the following trade(s): * On Thursday, July 9th, Adam Laponis sold 2,399 shares of Twist Bioscience stock. The shares were sold at an average price of $94.33, for a total transaction of $226,297.67. Twist Bioscience stock performance. Twist Bioscience stock traded up $16.33 during trading hours on Monday, hitting $205.00. The company had a trading volume of 3,203,579 shares, compared to its average volume of 1,622,926. The firm has a market cap of $12.86 billion, a PE ratio of -92.34 and a beta of 2.19. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $207.90. The firm has a 50-day moving average of $136.40 and a 200 day moving average of $92.42. Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. During the same quarter in the prior year, the firm earned $0.33 EPS. The company's revenue was up 23.2% on a year-over-year basis. On average, sell-side analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year. Analyst ratings changes. Several research firms have weighed in on TWST. UBS Group started coverage on Twist Bioscience in a research report on Wednesday, September 9th. They set a "neutral" rating and a $144.00 price objective on the stock. Barclays boosted their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an "overweight" rating in a research report on Wednesday, June 24th. Robert W. Baird upped their price target on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, August 4th. TD Cowen reiterated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Finally, Evercore downgraded shares of Twist Bioscience from an "outperform" rating to an "in-line" rating and set a $102.00 price objective for the company. in a report on Monday, July 6th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Twist Bioscience currently has an average rating of "Moderate Buy" and a consensus target price of $115.27. Key Twist Bioscience news. Here are the key news stories impacting Twist Bioscience this week: * Twist Bioscience reported approximately 23% year-over-year revenue growth in its latest quarter, reinforcing the company's expansion narrative and helping support bullish sentiment. * Leerink raised its price target for TWST from $120 to $160, signaling improved analyst expectations. Although the revised target remains below the recent share price, the increase may have added to buying momentum. * The stock reached a new 52-week high, reflecting strong momentum and investor demand. TWST has benefited from enthusiasm around biotechnology and synthetic-DNA markets, as well as attention from actively managed biotech funds. * CEO Emily Leproust, CFO Adam Laponis, CAO Robert Werner, SVP Paula Green and insider Dennis Cho sold shares primarily to cover tax withholding tied to vested equity awards. The transactions totaled roughly $14.3 million, but the CEO's sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their usefulness as a signal of deteriorating business prospects. * Valuation and profitability remain risks: the company continues to report net losses, and its latest quarterly earnings per share missed estimates despite beating revenue expectations. The sharp rally also leaves the stock well above Leerink's revised target, increasing the potential for volatility or profit-taking. Hedge funds weigh in on Twist Bioscience. Several hedge funds and other institutional investors have recently added to or reduced their stakes in TWST. BlackRock Inc. acquired a new stake in shares of Twist Bioscience during the 2nd quarter worth $600,191,000. William Blair Investment Management LLC bought a new position in shares of Twist Bioscience in the second quarter worth $223,722,000. Bank of America Corp DE acquired a new position in Twist Bioscience in the second quarter valued at about $94,922,000. Allspring Global Investments Holdings LLC bought a new stake in Twist Bioscience during the first quarter worth about $22,563,000. Finally, BNP Paribas Financial Markets lifted its position in Twist Bioscience by 242.2% during the fourth quarter. BNP Paribas Financial Markets now owns 415,609 shares of the company's stock worth $13,183,000 after purchasing an additional 294,144 shares during the period. Twist Bioscience company profile. Twist Bioscience Corporation NASDAQ: TWST is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods. The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Twist Bioscience, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list. While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates. Continue following MarketBeat

Twist Bioscience shares have surged 566% over the past year, far outpacing the S&P 500's 17% gain. The DNA synthesis company now trades at 26.6 times sales, compared with 3.1 times for the broader market. The company sells made-to-order DNA to drug makers and research labs. Revenue grew 22% annually over the past three years, but operating losses equalled 32% of sales in the latest period. Management attributes recent growth to drug developers using AI. Revenue from drug developers jumped 49% year-over-year to $40.4 million in fiscal Q3 2026. The company raised its fiscal 2026 revenue forecast to $456 million to $457 million. Management expects adjusted EBITDA to reach break-even in fiscal Q4 2026. However, in fiscal Q3, adjusted EBITDA showed a loss of $11.3 million. The next test comes in November when management issues fiscal 2027 guidance.

TWST jumps as Twist Bioscience lands Lilly AI drug discovery deal. MATT MONACO - UPDATED SEP. 19, 2026, 11:07 AM ET Twist Bioscience Corporation stocks have been trading up by 7.1 percent following highly positive sentiment around its latest developments. What traders need to know. * Twist Bioscience signed an agreement to provide antibody characterization data and services to Eli Lilly's AI/ML drug discovery platform, TuneLab, integrating its wet-lab protocols into Lilly's AI models. * Shares of TWST rose, in some reports by more than 4%, after the Lilly TuneLab antibody characterization data services agreement was announced. * Leerink raised its price target on Twist Bioscience from $120 to $160 and reiterated an Outperform rating, leaning on a large, early-stage AI drug discovery opportunity. * UBS initiated coverage of TWST with a Neutral rating and a $144 price target within a broader life science tools initiation that sees the sector outgrowing global GDP over time. * The company said its pilot work on AI-designed mini-binder proteins for Anthropic is already "probably sort of" embedded in its fiscal 2027 orders outlook, not incremental to current guidance. Weekly Update Sep 14 - Sep 18, 2026: On Saturday, September 19, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 7.1%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Healthcare industry expert: Analyst sentiment - positive Twist Bioscience occupies a differentiated position in synthetic DNA and antibody discovery, with strong 52% gross margins and nearly 10% three-year revenue CAGR off a $377M base, but remains structurally loss-making (EBIT margin ~-32%, ROE ~-30%). Cash burn is material: Q3 free cash flow was -$8.6M despite positive $1.1M operating cash flow largely driven by $18M stock-based comp. Balance sheet risk is contained near term, with current ratio 2.7 and modest leverage (total debt/equity 0.21). The stock is in a powerful short-term uptrend: from $133.41 close on 9/14 to $166.60 on 9/18, with successive higher highs and no material intraday reversals, indicating aggressive buying following the news flow. The 9/17-9/18 range ($155-167) is the new control zone; $155 emerges as first meaningful support and a clear risk-management line. For active traders, pullbacks toward $155 with stabilizing intraday volume offer high-reward entries, targeting a retest and extension above $170. Lilly TuneLab and Anthropic mini-binder work firmly position Twist at the intersection of synthetic biology and AI drug discovery, a structural growth vector well ahead of the broader Healthcare and Diagnostics & Screening groups. The Leerink PT hike to $160 and UBS's $144 initiation validate institutional demand for the AI narrative despite ongoing losses. I see the risk-reward skewed favorably: accumulate on dips toward $155 support, with a 6-12 month upside target zone of $185-$200 and technical resistance beginning near $175. Quick financial overview. Twist Bioscience Corporation is trading in a strong upswing, with the weekly chart showing a move from $133.41 to $166.60 over the recent data window. That is a sharp multi-day leg higher, reinforced by intraday action where price ran from an open near $158 to a session high above $167 before closing just under that high. For short-term traders, that is classic momentum behavior: buyers in control, shallow intraday pullbacks, and a close near the top of the day's range. The Lilly TuneLab agreement is driving this surge, as TWST locks its antibody characterization workflows directly into Eli Lilly's AI/ML drug discovery platform. Multiple reports tie the share price pop, including gains of more than 4% on one session, to this AI collaboration. On the Street side, Leerink lifting its price target from $120 to $160 with an Outperform call, and UBS coming in at $144 with a Neutral, both anchor expectations well above prior averages and help explain why traders are willing to chase strength. Under the hood, Twist Bioscience generated about $376.57M in revenue over the trailing period, with a healthy 52% gross margin but deep negative profitability metrics, including an EBIT margin near -31.8% and returns on equity around -29%. The latest quarterly report (period ending 2026/06/30) shows $118.38M in revenue but a net loss of roughly $35.05M and EBITDA of about -$27.96M, although operating cash flow turned slightly positive at $1.12M. Balance sheet strength is reasonable for a high-growth name, with a current ratio of 2.7 and total debt to equity at 0.21, but valuation is rich, with price-to-sales around 23.89 and price-to-book over 23, which helps explain why some analysts stay cautious even as they set high absolute targets. Conclusion. This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Its content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to Millionaire Media, LLC. for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize its news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities. Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles: Once you've got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market's twists and turns. Dig into StocksToTrade's watchlists here: One-of-a-kind AI play revealed. If you'd put $2,000 into Nvidia back in 2020, you'd be sitting on more than $30,000 today. The stock's been an absolute monster... But if you think you missed the boat, then you need to see this urgent message TODAY. Because not only am I revealing why the REAL AI boom is only just getting started... I'm also going to show you my top AI recommendation that's been CRUSHING it in this market. It has nothing to do with Nvidia... or Meta... or OpenAI... or anything else you're probably thinking. It's a unique AI play I'm certain you're not hearing from anyone else... One that could give you the chance to target an entire YEAR of peak Nvidia potential... In just one day. How much has this post helped you? (0 votes, average: 0 out of 5)